Abstract Number: 1823 • 2019 ACR/ARP Annual Meeting
Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity
Background/Purpose: Prevalence of sacroiliitis (SI) in Crohn’s disease (CD) varies widely (range 4% -39%), depending on criteria utilized to define the disease (e.g. inflammatory back…Abstract Number: 2883 • 2018 ACR/ARHP Annual Meeting
Testing for Anti-Microbial Antibodies with Cross-Reactivity to Human Tissue in Autoimmune Diseases
Background/Purpose: Autoantibodies are defining features of autoimmune diseases. How and why the autoantibodies are produced and how these autoantibodies relate to pathogenesis is poorly understood.…Abstract Number: 367 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors
Background/Purpose: IBD is often associated with other CID, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (PsO). Newer biologic agents…Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…Abstract Number: 2514 • 2018 ACR/ARHP Annual Meeting
Development of a Subcutaneous Formulation of CT-P13 (Infliximab): Maintenance Subcutaneous Administration May Elicit Lower Immunogenicity Compared to Intravenous Treatment
Background/Purpose: Intravenous (IV) use of CT-P13, an infliximab (INX) biosimilar, has resulted in comparable efficacy, safety and immunogenicity as innovator INX in various indications including…Abstract Number: 372 • 2017 ACR/ARHP Annual Meeting
Phenotype of Chronic Recurrent Multifocal Osteomyelitis in a Tertiary Referral Centre: The Great Ormond Street Hospital Experience
Background/Purpose: Recurrent Multifocal Osteomyelitis (CRMO) is an aseptic inflammatory bone disease that typically affects the metaphases of the long bones. It affects children, adolescents and…Abstract Number: 594 • 2017 ACR/ARHP Annual Meeting
Imaging Biomarkers in Crohn’s Associated Axial Spondyloarthritis
Background/Purpose: Axial SpA has been reported in 4-16% of patients with Crohn's disease (CD). However, some plain radiograph or magnetic resonance imaging (MRI) studies in…Abstract Number: 1047 • 2017 ACR/ARHP Annual Meeting
Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing
Background/Purpose: Adalimumab (ADA) induces and maintains clinical remission in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD) but is an expensive drug. Drug-level and…Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…Abstract Number: 1726 • 2016 ACR/ARHP Annual Meeting
An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Background/Objective:Therapeutic decisions are based on efficacy, but clinicians need to consider medication safety in this process. Here, we report ustekinumab (UST) integrated safety data in…Abstract Number: 906 • 2015 ACR/ARHP Annual Meeting
Distinct Expression of IL-36α, β, γ and Their Antagonists IL-36Ra and IL-38 in Psoriasis, Rheumatoid Arthritis and Crohn’s Disease
Background/Purpose: The IL-36 family of cytokines comprises three agonists, IL-36α, IL-36β and IL-36g, an antagonist IL-36Ra, as well as IL-38, another potential IL-36 inhibitor. IL-36…Abstract Number: 2061 • 2015 ACR/ARHP Annual Meeting
Uncovering Crohn’s Disease in Patients with Spondyloarthropathies Using Videocapsule Endoscopy
Background/Purpose: Inflammatory bowel disease (IBD) is clinically associated with spondylarthropathies (SpA) in 5-15% of cases. Protocol colonoscopic assessment demonstrated asymptomatic inflammation characteristic of Crohn’s disease…Abstract Number: 2284 • 2014 ACR/ARHP Annual Meeting
Joint Involvement in Pediatric Crohn’s Disease Is Related to Higher Disease Activity and Worse Quality of Life
Background/Purpose: The incidence of arthritis and arthralgia in pediatric patients with Crohn's disease (CD) is reported to be 2–15% and 22%, respectively. The aim of our…Abstract Number: 2209 • 2014 ACR/ARHP Annual Meeting
Novel Biomarkers of Extracellular Matrix Remodeling in Inflammatory Bowel Disease: Different Patterns of Gut Injury in UC and CD
Background/Purpose: About 10 % of patients with IBD have symptoms that match both Crohn's disease (CD) and ulcerative colitis (UC), termed inflammatory bowel disease unclassified…
ACR Meeting Abstracts